Document Detail

Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration.
MedLine Citation:
PMID:  22678809     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To compare the results of combination therapy with different intervals between intravitreal bevacizumab and photodynamic therapy (PDT) with verteporfin for age-related macular degeneration.
METHODS: Treatment-naïve eyes (n = 184) with 12 months' follow-up were included in this retrospective case series. Eyes were classified according to the interval between bevacizumab and PDT administration: group D1, 1-day interval (n = 116); group D7, 7-day interval (n = 68). The study was conducted at two hospitals, with group D1 evaluated in one hospital and group D7 evaluated in the other. The main outcome measure was comparison of the increases in best-corrected visual acuity (BCVA) of the two groups 3 and 12 months after the initial treatment by means of analysis of covariance (ANCOVA).
RESULTS: Group D1 gained 1.3 lines and group D7 gained 1.5 lines of BCVA at 3 months; group D1 gained 0.8 lines and group D7 gained 1.4 lines at 12 months. There was a significant difference between the groups in the increased BCVA levels at 3 months (P = 0.0450) and a trend toward significance at 12 months (P = 0.0516). ANCOVA analysis revealed that baseline BCVA, hemorrhagic pigment epithelial detachment, subretinal fluid, lesion size, and a 7-day treatment interval were significantly correlated with the increase in the BCVA at 3 months.
CONCLUSIONS: A 7-day treatment interval might offer slightly better visual acuity gain in the short term than a 1-day interval.
Miki Sawa; Eiji Iwata; Kohei Ishikawa; Fumi Gomi; Kohji Nishida; Hiroko Terasaki
Related Documents :
15285799 - Effect of pioglitazone treatment in a patient with secondary multiple sclerosis.
22371539 - The early radiological results of the uncemented oxford medial compartment knee replace...
22759089 - Using quarterly earnings to assess racing performance in 70 thoroughbreds after modifie...
1813439 - 5-aminosalicylic acid in the prevention of relapses of crohn's disease in remission: a ...
9253309 - Medical therapy of graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
22539159 - Resting energy expenditure after fontan surgery in children with single-ventricle heart...
7936569 - Orbital reconstruction using porous polyethylene sheets.
18064399 - Laparoscopic ventral hernia repair (lvhr) in morbidly obese patients.
23159839 - Direct-acting antiviral therapies for hepatitis c genotype 1 infection: a multiple trea...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2012-06-09
Journal Detail:
Title:  Japanese journal of ophthalmology     Volume:  56     ISSN:  1613-2246     ISO Abbreviation:  Jpn. J. Ophthalmol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-13     Completed Date:  2012-11-30     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0044652     Medline TA:  Jpn J Ophthalmol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  470-5     Citation Subset:  IM    
Department of Ophthalmology, Osaka University Graduate School of Medicine, Room E7, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Coloring Agents / diagnostic use
Combined Modality Therapy
Fluorescein Angiography
Indocyanine Green / diagnostic use
Intravitreal Injections
Middle Aged
Photosensitizing Agents / administration & dosage
Porphyrins / administration & dosage
Retrospective Studies
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Wet Macular Degeneration / diagnosis,  drug therapy*,  physiopathology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Coloring Agents; 0/Photosensitizing Agents; 0/Porphyrins; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 129497-78-5/verteporfin; 2S9ZZM9Q9V/bevacizumab; 3599-32-4/Indocyanine Green

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  [Analysis of allelic drop-out at short tandem repeat loci].
Next Document:  Wedelolactone inhibits adipogenesis through the ERK pathway in human adipose tissue-derived mesenchy...